Skip to content
‹ Back to IndustriesSciences

Takara Bio and SPT Labtech pair SMART-Seq kits with firefly automation scripts

SPT Labtech and Takara Bio USA are teaming up to offer validated, automated workflows for library preparation, pairing Takara Bio's NGS library prep chemistries with the firefly liquid handler from SPT Labtech. Two SMART-Seq kits are available for download today. Due to ship in January 2027, the SMART-Seq mRNA Long Read Extended kit is set to be the first product to launch with a workflow tuned for firefly automation.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By MarketScale Newsroom · Takara BioSpt LabtechFireflySmart-seq
Share
Takara Bio and SPT Labtech pair SMART-Seq kits with firefly automation scripts

Key takeaways

01

For sequencing cores on SPT Labtech's firefly, Takara Bio says automated workflows will be built into new kits from the start, which suggests more of the method-building could happen at the vendors before the box reaches the bench.

02

Whether DNA-seq and immune profiling kits arrive with firefly scripts on their launch dates will show if this becomes standard practice or stays an RNA-seq offering.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Takara Bio's first product to launch with a workflow tuned for firefly automation will be the SMART-Seq mRNA Long Read Extended kit, which is due to ship in January 2027. On October 20, Takara Bio USA and SPT Labtech said they will work together to develop and verify automated library preparation workflows that run Takara Bio's next-generation sequencing (NGS) chemistries on the firefly liquid handling platform from SPT Labtech. SMART-Seq RNA-seq kits come first. The companies then plan to cover new RNA-seq, DNA-seq and immune profiling kits.

The announcement came jointly from San Jose and Cambridge, UK, on the opening day of the American Society of Human Genetics (ASHG) Annual Meeting, held October 20, 24 in Montreal, where both companies planned to exhibit and present posters. Takara Bio USA is a wholly owned subsidiary of Takara Bio Inc., so the launch-package commitment covers the chemistry side of the house, with SPT Labtech supplying the hardware and script distribution.

The companies' joint release says Takara Bio is building automation into its NGS technology launch package, so labs can go from evaluating a product to running it routinely at scale in less time. Andrew Farmer, president and CEO of Takara Bio USA, described this as a shift in how the company sells. He said the work with SPT Labtech is turning automation into a core part of the way Takara Bio takes NGS products to market. He added that customers should expect new library prep products to come with automated workflows from day one.

That matters most to the people the release names as the target: NGS core labs and other high-volume library prep operations that want to expand their capabilities but are short on staff, bench space or budget. The Scientist, in its coverage of the launch, called library preparation the throughput bottleneck for sequencing cores even as instrument costs fall. It also cited a 2022 BMC Genomics benchmark that found meaningful differences in gene detection sensitivity across full-length single-cell RNA-seq workflows.

The Scientist read that evidence as reinforcing the value of validated, ready-to-run automation. The logic is straightforward: if the choice of workflow measurably moves what a lab detects, then the method itself becomes something worth fixing in place, and a pre-verified script is one way to fix it.

Two SMART-Seq workflows running today

Labs do not need to hold off until January. SPT Labtech's cloud portal already offers downloadable scripts for two kits on the market today, each including unique molecular identifiers (UMIs): SMART-Seq Total RNA Library Prep with ZapR Depletion and SMART-Seq mRNA LP. A technical note covering SMART-Seq mRNA LP on firefly is also available.

SMART-Seq workflows supported on firefly

10 pg
Lowest input for SMART-Seq mRNA LP, down to a single cell
250 pg, 1 µg
Total RNA input range for the ZapR kit, including degraded and FFPE samples
384
Maximum libraries for each of the two Illumina workflows available now
96
Maximum libraries for the Long Read Extended kit shipping January 2027

The Scientist; Takara Bio USA and SPT Labtech

One handles very low-input and single-cell work. The other takes 250 pg to 1 µg of total RNA, including degraded and FFPE samples. Both kits produce multiplexed libraries ready for Illumina sequencers.

Between them, the two scripts span very different sample types, from a single cell at one end to degraded FFPE material at the other. For a core that takes work from many research groups, that range suggests the first release was chosen to cover common short-read requests rather than a niche application.

SMART stands for Switching Mechanism at 5' End of RNA Template, the chemistry behind Takara Bio's full-length cDNA kits. UMIs are short molecular tags that let analysis software count the original molecules, which reduces the amplification bias that can skew expression data.

A benchtop robot with an audit trail

The Scientist reports that firefly, sold as firefly 3 and firefly 6, puts four capabilities (pipetting, dispensing, incubation and shaking) in one compact benchtop unit. An add-on called firefly+ adds a thermocycler for hands-free library prep from start to finish. Paul Lomax, head of genomics at SPT Labtech, said in the release that the aim is to give labs automated library prep without the infrastructure that larger automation platforms often need.

"We believe automation should be a practical option for every genomics lab," Lomax said, pointing to firefly's all-in-one design and small footprint. The companies say the platform is meant both for labs that already automate and for those setting up automated workflows for the first time, and that the jointly built workflows are simple to integrate into existing processes.

According to the companies, firefly's intuitive programming environment, configurable user permissions and transparent audit trail support standardization across teams. They also say firefly's peer-to-peer cloud network lets laboratories access verified methods directly, which helps reduce time to first run and improve consistency across sites.

Those controls would matter most in a core where several staff run the same method on behalf of many users. Permissions limit who can change a verified script, and the audit trail records what actually ran, which is the kind of reproducibility Lomax described as needed for routine sequencing operations.

A Cambridge core helped build the ZapR method

The NGS Hub at the University of Cambridge's Stratified Medicine Core Laboratory worked with both companies to automate the Total RNA ZapR workflow on firefly. Ana Luisa Toribio, head of the hub, said in the release that her researchers brought real-world operating experience to the method, aiming for deep sequencing results that hold up run after run. She said that for a flagship facility running multi-omics research from start to finish, nothing matters more than data depth and reproducibility that admit no compromise.

The release frames this kind of partnership around what high-volume sequencing cores keep chasing: throughput, reproducibility and operational efficiency. The ZapR kit is the one built for degraded and FFPE inputs, so having a working core help shape its automated version suggests the script was tested against a demanding sample type, not only clean reference material.

Long reads come with a lower library ceiling

The January kit is a different kind of product. SMART-Seq mRNA Long Read Extended is built for Oxford Nanopore Technologies sequencers, not Illumina. According to Takara Bio, the kit accepts a wider range of inputs and recovers more full-length transcripts, which supports isoform discovery, detection of gene fusions and analysis of alternative splicing. The Scientist's comparison table lists a maximum of 96 libraries for it, a quarter of the 384 shown for each short-read workflow.

Like the two short-read kits, it carries UMIs, which the release ties to greater quantitation confidence. The companies pitch the kit-plus-script pairing as a way to standardize long-read transcriptomics at scale with increased operational efficiency.

Long-read protocols are more complex, which The Scientist noted with reference to a 2025 Genome Research perspective on the method challenges long-read RNA-seq still faces, arguing that the added complexity raises the stakes for manual variability. Automation helps most where manual variation is a risk. That puts the long-read kit where a verified script should pay off most, and also where the 96-library ceiling bites: matching one maximum short-read batch would take four long-read batches.

Before planning a long-read rollout, check whether a 96-library maximum fits the batch sizes the core actually runs on Oxford Nanopore, and how many extra runs a typical project would take compared with the 384-library short-read workflows.

January shows whether the model holds

For a core running firefly, the method-building work now happens at Takara Bio and SPT Labtech, which jointly build and verify the automation scripts. That suggests the core's own job shifts from writing a method to downloading one and checking it against local samples.

The bigger test comes later. If the promised DNA-seq and immune profiling kits arrive with firefly scripts on their launch dates, script-at-launch becomes how Takara Bio sells NGS chemistry. If they arrive months behind the reagents, it stays an RNA-seq convenience.

Featured companies

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

MarketScale Newsroom
MarketScale NewsroomEditorial Team, MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Merck KGaA moves Rapid Micro’s Growth Direct from distribution to ownership for QC labs

Merck KGaA moves Rapid Micro’s Growth Direct from distribution to ownership for QC labs

Merck KGaA agreed to buy Rapid Micro Biosystems, maker of the Growth Direct microbial testing platform, for $0.75 per share in cash. The deal turns a 2025 distribution partnership into ownership. Growth Direct instruments, consumables and software would then come from the company that already sells QC products to pharma labs, pending a December 2026 close.

  • 01Growth Direct shifts from a Merck-distributed product, under a February 2025 agreement, to a Merck-owned one inside a QC portfolio that spans environmental monitoring, in-process and release testing.
  • 02For labs that already run Growth Direct alongside MilliporeSigma QC products, the useful question is how the platform's digital sample records will connect to the rest of that workflow after close.
  • 03The next date to watch is the Schedule TO filing that opens the tender offer; closing targeted for December 2026 requires a majority of Rapid Micro’s voting shares to be tendered.

Nov 17, 2026

SR-Tiget gene therapy families average six months in Milan and years of lab tests

SR-Tiget gene therapy families average six months in Milan and years of lab tests

Gene therapy at Milan’s SR-Tiget includes a family support programme that helps relatives manage months-long stays (often around six months) for treatment, while a regulated lab can track patient samples for up to 20 years. Follow-up visits can outnumber new treatments, adding to the long-term workload.

  • 01In 2025, the programme logged 133 follow-up visits against 17 treatments; with roughly 15 years of twice-yearly checkups per patient, the follow-up load is likely to keep growing even if new treatments stay flat.
  • 02At SR-Tiget, the average family spends six months in Milan, and the child's samples can keep reaching the lab for as long as twenty years.
  • 03Any gene therapy service has to answer one question: who tells the lab when a child's fever pushes a blood draw from morning to afternoon? In Milan, research nurses own that handoff.

Nov 16, 2026

Two photonic AI components reach outside testers—limited access

Two photonic AI components reach outside testers—limited access

Kopin is expanding microLED manufacturing in Westborough, Massachusetts, which could add up to 80 jobs over five years. Its microLEDs will go to military displays and to Neural I/o, an interconnect that sends AI data as light. In the same news round-up, Q.ANT and IONOS opened a photonic processor pilot where approved applicants can run their own workloads.

  • 01Two photonic approaches tied to AI’s power problem reached testable hardware this month: PsiQuantum’s 8×8 optical switch samples and Q.ANT’s second-generation processor via an IONOS bare-metal pilot in Germany.
  • 02PsiQuantum is sending samples of an 8×8 demonstration optical circuit switch to selected prospective customers, giving buyers hardware they can test even though commercial products and full specs are still pending.
  • 03Staffing may not keep up with demand: a 2023 Applied Optics study projected US demand for 42,000 new middle-skilled photonics workers by 2030, and Kopin’s expansion adds another competitor for photonics technicians in Massachusetts.

Nov 15, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

MarketScale Newsroom
MarketScale Newsroom

Editorial Team

MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512